Treatment  ||| S:0 E:10 ||| NN
and  ||| S:10 E:14 ||| CC
timing  ||| S:14 E:21 ||| NN
in  ||| S:21 E:24 ||| IN
invasive  ||| S:24 E:33 ||| FW
mould  ||| S:33 E:39 ||| FW
disease  ||| S:39 E:47 ||| FW
Invasive  ||| S:47 E:56 ||| FW
mould  ||| S:56 E:62 ||| FW
disease  ||| S:62 E:70 ||| NN
is  ||| S:70 E:73 ||| VBZ
a  ||| S:73 E:75 ||| DT
growing  ||| S:75 E:83 ||| VBG
threat  ||| S:83 E:90 ||| NN
for  ||| S:90 E:94 ||| IN
immunocompromised  ||| S:94 E:112 ||| JJ
patients ||| S:112 E:120 ||| NNS
.  ||| S:120 E:122 ||| .
The  ||| S:122 E:126 ||| DT
optimum  ||| S:126 E:134 ||| JJ
time  ||| S:134 E:139 ||| NN
to  ||| S:139 E:142 ||| TO
use  ||| S:142 E:146 ||| VB
mould-active  ||| S:146 E:159 ||| JJ
antifungal  ||| S:159 E:170 ||| JJ
agents  ||| S:170 E:177 ||| NNS
is  ||| S:177 E:180 ||| VBZ
much  ||| S:180 E:185 ||| RB
debated ||| S:185 E:192 ||| VBN
.  ||| S:192 E:194 ||| .
Current  ||| S:194 E:202 ||| JJ
approaches  ||| S:202 E:213 ||| NNS
to  ||| S:213 E:216 ||| TO
antifungal  ||| S:216 E:227 ||| VB
prophylaxis ||| S:227 E:238 ||| NNS
,  ||| S:238 E:240 ||| ,
early  ||| S:240 E:246 ||| JJ
treatment  ||| S:246 E:256 ||| NN
( ||| S:256 E:257 ||| -LRB-
empirical  ||| S:257 E:267 ||| NN
and  ||| S:267 E:271 ||| CC
pre-emptive  ||| S:271 E:283 ||| JJ
therapy ||| S:283 E:290 ||| NN
)  ||| S:290 E:292 ||| -RRB-
and  ||| S:292 E:296 ||| CC
treatment  ||| S:296 E:306 ||| NN
of  ||| S:306 E:309 ||| IN
documented  ||| S:309 E:320 ||| JJ
mould  ||| S:320 E:326 ||| JJ
infections  ||| S:326 E:337 ||| NNS
in  ||| S:337 E:340 ||| IN
onco-haematology  ||| S:340 E:357 ||| JJ
patients  ||| S:357 E:366 ||| NNS
are  ||| S:366 E:370 ||| VBP
discussed ||| S:370 E:379 ||| VBN
.  ||| S:379 E:381 ||| .
